0806 Prescription Correlates of Nightmare Disorder Among Veterans

Introduction

In the James A. Haley Veterans Administration (JAHVA) Vista database, the ICD-9 code 307.47 for Nightmare disorder (ND) is infrequently used and appears independently of codes for PTSD. We wanted to determine if certain drugs that may affect sleep are associated with ND.

Methods

All patients with ND visiting JAHVA between 2007 and 2011 were selected along with control patients who visited JAHVA on one of 20 random days, one day each quarter year. Controls were assigned an index date reflecting their selection quarter. Associations with prescriptions for opioids, antidepressants (SSRI’s, SSNI’s, Tricyclics), antihistamines and benzodiazepine/Z-drugs were initially investigated. Two analyses were performed: risk factor analysis- patients with ND diagnosis dates (cases) or index dates (controls) prior to 2008 were excluded and only prescription dates that preceded the ND diagnosis or index date were considered; treatment analysis- cases and controls with a ND diagnosis date or index date after 2010 were excluded and only prescription dates that were subsequent to the ND diagnosis or index date respectively were considered. Logistic regression adjusting for age, gender, race and Hispanic ethnicity was used to determine the association between drug groups and ND.

Results

In risk factor analysis (667 cases, 14,739 controls), opioids and antihistamines were significantly less prevalent among would-be ND patients than controls (OR=0.627 and 0.610 respectively); no drug group was predictive of ND. In contrast, all drug groups were significantly associated with ND in treatment analysis (803 cases, 15,530 controls). The strongest associations were seen with benzodiazepine (OR=3.026; 95% CI: 2.472, 3.703) and SSRI (OR=2.789; 95% CI=2.316, 3.358) prescriptions.

Conclusion

Our data suggest that some JAHVA providers may be treating ND with medication, most notably with benzodiazepines/Z-drugs and antidepressants. The role of anti-histamine and opioid prescriptions needs further elucidation. The ramifications of these treatment decisions should be explored.

Support

This material is the result of work supported with resources and the use of facilities at the James A. Haley Veterans’ Hospital.

The Effect of Hemodialysis on the Expression of Platelet Glycoproteins Ib, IIb/IIIa and P-Selectin

To determine the effect of hemodialysis on expression of platelet receptors in patients with chronic renal failure.

DESIGN

Blood sampling performed in chronic HD patients prior to the dialysis session, then 15 and 180 minutes into HD. Both dialysis machine inlet and outlet samples were taken at 15 minutes. Control subjects had a single blood sample taken.

PATIENTS

Thirteen adult males on chronic hemodialysis and 20 age and sex matched healthy controls.

MEASUREMENTS

Flow-cytometric analysis of platelet GP-Ib, GP-IIb/IIIa, and P-selectin. Plasma vWF multimers were analyzed by SDS-polyacrylamide gel electrophoresis and immunoblotting.

RESULTS

Mean channel fluorescence (MCF) for GP lb was significantly (P < 0.05) decreased in pre-dialysis patients compared to controls and decreased further 3 hours into the dialysis session compared to the start of the dialysis treatment (P < 0.01). MCF for GP IIb/IIIa between predialysis patients and controls was similar, but decreased after a single dialysis session (P < 0.01). MCF for P-selectin on platelets was similar in patients and controls, but fewer platelets from the patients expressed P-selectin compared to controls (P < 0.05). Qualitative multimeric analysis of the vWF in patients, pre- and post-HD was unchanged.

CONCLUSIONS

Alterations in platelet surface expression of GPIb, GPIIb/IIIa, and P-selectin may, partially contribute to the changes in platelet function seen in patients on hemodialysis. It is unlikely that alterations in the surface expression of these receptors alone can adequately account for the complex platelet and hemostatic changes associated with uremia and the HD procedure.

Mesenteric artery embolization by an unsuspected aortic tumor: diagnostic evaluation and operative management

Malignant tumor embolus recovered at the time of superior mesenteric artery embolectomy is an uncommon experience. A report of such a case is presented and the literature is reviewed. In this clinical setting, guidelines for further diagnostic evaluation are not well defined. We suggest an algorithm for the evaluation and management of these patients. In the near future, use of intraoperative angioscopy and the intravascular laser to eradicate the tumor may represent the optimal method of treatment.